Nature Biotechnology
In early Dec 2010, Cephalon made an up-front payment of $130 million to Mesoblast to develop and commercialize adult mesenchymal precursor cell therapies for a multitude of disorders, ranging from congestive heart failure and neurodegenerative diseases to cancer. Cephalon has also paid $220 million...
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2011-02, Vol.29 (2), p.97 |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | In early Dec 2010, Cephalon made an up-front payment of $130 million to Mesoblast to develop and commercialize adult mesenchymal precursor cell therapies for a multitude of disorders, ranging from congestive heart failure and neurodegenerative diseases to cancer. Cephalon has also paid $220 million for a 19.99% equity stake and a seat on the board of Mesoblast. |
|---|---|
| ISSN: | 1087-0156 1546-1696 |
| DOI: | 10.1038/nbt0211-97a |